Rewiring the biology of immune cells to improve outcomes for patients with aggressive cancers.

learn more

Our Research

Our lab is focused on harnessing the power of single cell and computational biology to study and model how human immune cells sense and respond to their environment. We start by innovating new experimental and computational methods that enable the profiling and analysis of immune cells at unprecedented resolution, precision, and scale. We use these tools to systematically dissect immune circuits in health and disease. In healthy donors, we measure the natural variability in immune response and model how genetics and biological rhythms tune immune circuits to affect a person’s risk for disease or response to treatment. In patients with infectious disease, autoimmunity, neurodegeneration and cancer, we search for common failure modes in immune circuits and identify novel targets for therapeutic intervention. Building on this work, the lab is initiating new efforts to translate our insights into design specifications that can aid the development of personalized medicines and engineered immune circuits for future therapeutic strategies.  

Tldr: we build tech, write code, study immunology, and develop medicine.

Our Partners

Our goal is to engineer superior cell therapies for cancer patients.

Our work starts by developing and harnessing the power of unbiased CRISPR-based discovery platforms to identify novel gene targets that can be manipulated in immune cells to drive more therapeutic behaviors.

learn more

Our People

We are a closely integrated group of researchers driven by a common goal, to accelerate the discovery of effective cell therapies for cancer patients. As a new lab situated within the highly collaborative Gladstone-UCSF Genomic Immunology Institute, we benefit from exciting partnerships with other labs combined with an agile team-oriented approach to accelerate the trajectory of our work.

meet our team

Stay Updated

Keep up-to-date with the latest research from the Carnevale lab.